TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (âProfoundâ or the âCompanyâ), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).
Related Questions
How does the company's valuation metrics (P/E, EV/EBITDA, priceâtoâsales) compare to peers in the medicalâdevice/AIâmedtech sector?
Did the company provide guidance for Q3 2025 and fullâyear 2025 earnings, revenue, and cash flow?
What was the performance of the core AIâpowered, incisionâfree product portfolio versus the prior period?
How did Profound Medical's Q2 2025 revenue compare to consensus analyst estimates?
What was the yearâoverâyear growth rate for revenue and net income in Q2 2025?
What are the key drivers behind the reported revenue growth or decline in this quarter?
How does the current cash position and runway compare to previous quarters and the upcoming capital needs?
What are the trends in the company's gross margin and operating expenses, especially R&D and SG&A?
Are there any notable regulatory approvals, product launches, or pipeline milestones mentioned?
What is the impact of foreignâexchange fluctuations and other nonârecurring items on the results?
Did the company disclose any significant contract wins, partnerships, or supplyâchain updates that could affect future revenue?
What are the potential risks or headwinds highlighted in the MD&A that could affect future performance?